ORLADEYO recommended for public reimbursement in Québec, Canada

BioCryst Pharmaceuticals announced that ORLADEYO has been recommended for public reimbursement in Québec, Canada

BioCryst Pharmaceuticals today announced that the Institut national d’excellence en santé et services sociaux (INESSS) has issued a positive recommendation for ORLADEY (berotralstat) to be reimbursed for the prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age and older in Québec.

Anand Janack, vice president and general manager of BioCryst Canada, said: “We are committed to bringing ORLADEYO to as many Canadians living with HAE as possible. This announcement from INESSS, which follows the positive recommendation from CADTH earlier this year, takes us one step closer to making our oral, once-daily therapy available to Canadians who are in need of a new option to help improve control of their HAE attacks.”

ORLADEYO (berotralstat) is an oral, once-daily treatment for prevention of HAE attacks.

(Source: BioCryst Pharmaceuticals)